Mary Mullins, NP
Neuromusculoskeletal Medicine & OMM · Centennial, CONPI 1073641049
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 47.1% of the total.
Across 211 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$561
- Lilly USA, LLC$168
- GSK$93
- Eisai Inc.$92
- Novo Nordisk$88
- plus $800 from 23 others
What the payments were for
- Food & beverage$3,409100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,607 |
| AstraZeneca | 26 | $561 |
| Lilly USA, LLC | 18 | $168 |
| GSK | 5 | $93 |
| Eisai Inc. | 3 | $92 |
| Novo Nordisk | 5 | $88 |
| Astellas Pharma US Inc | 5 | $87 |
| Pfizer | 5 | $80 |
| Merck | 5 | $72 |
| Amgen | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $53 |
| Johnson & Johnson | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $48 |
| Exact Sciences | 3 | $48 |
| Boston Scientific | 3 | $45 |
| Vertex | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Edwards Lifesciences | 1 | $25 |
| Seqirus USA Inc | 1 | $18 |
| Abbott | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Corium, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Inogen, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromusculoskeletal medicine & omm providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $60,511 |
| EliquisApixaban | 37 | $49,753 |
| JardianceEmpagliflozin | 30 | $44,709 |
| FarxigaDapagliflozin Propanediol | 37 | $42,712 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $36,803 |
| XareltoRivaroxaban | 26 | $30,828 |
| JanuviaSitagliptin Phosphate | 20 | $27,587 |
| Atorvastatin Calcium | 429 | $3,549 |
| Levothyroxine Sodium | 287 | $2,268 |
| Gabapentin | 92 | $2,222 |
| Duloxetine Hcl | 73 | $2,033 |
| Omeprazole | 124 | $1,992 |
| SynthroidLevothyroxine Sodium | 31 | $1,428 |
| Nebivolol Hcl | 16 | $1,424 |
| Ibandronate Sodium | 36 | $1,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $88 | $60,51136 claims |
| PfizerEliquis | $80 | $49,75337 claims |
| Boehringer IngelheimJardiance | $12 | $44,70930 claims |
| AstraZenecaFarxiga | $561 | $42,71237 claims |
| GSKTrelegy Ellipta | $93 | $36,80326 claims |
| Johnson & JohnsonXarelto | $53 | $30,82826 claims |
| MerckJanuvia | $72 | $27,58720 claims |
| AbbVieSynthroid | $1,607 | $1,42831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine & omm in Centennial
- David TannerBoulder$13K
- Alex ReishBoulder$9K
- Emily GibsonEnglewood$183
- Craig MaplesCastle Rock$126
- Victoria TuttleEnglewood$111
- Daniel LopezDenver$97
- Emmy Lawrason-KobobelDurango$84
- Joel CoopermanAurora$76
- Debra ConfortiThornton$63
- Sarah HousmanPueblo$49
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.